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Takeda Pharmaceutical Company Limited 
• Takeda is a research-based global 
pharmaceutical company founded in 1781 
with global headquarters in Osaka, Japan. 
• Takeda is the largest pharmaceutical 
company in Japan with operations in more 
than 70 markets worldwide and 
approximately 31,000 employees. 
• For more than two centuries, Takeda has 
continued its mission to strive towards better 
health for patients worldwide through leading 





Takeda is a Leading Global Pharmaceutical 
Company 
Chobei Takeda I 
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Quotes from Gro Brundland, Jeffrey Sachs, Kofi Annan, Julio Frenck, Bill Gates and others 
Why is Takeda Pursuing a Global Vaccine Business? 
…because it is high-impact, focused on prevention, and driven by innovation  
“The most successful and cost-effective 
health care intervention, second only to 
clean drinking water” 
 
“Vaccines prevent 3-4M deaths / year” 
 
“New vaccines / better global use of 
existing vaccines could prevent another 
4-7M deaths” 
 
“The single most important tool to reach 
the 2000 UN Millennium Development 
Goals” 
 
“We must make this the Decade of 
Vaccines” 
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Noroviruses are currently recognized as the leading 






2 M hospitalized 
 
25 M clinic visits 
 
111 M episodes of 
gastroenteritis 
requiring only 
home care  
Rotavirusc  
5 
c worldwide children <5 yrs of age 
      Parashar et al, EID, 2003 
According to the CDC, “The perfect human pathogen” 
2016 median 
estimate of 699 
million cases of 
norovirus illness 
Bartsch et al PLoS 2016 
Norovirus – “The Perfect Human Pathogen”    
 Genetically diverse and environmentally stable 
− Family Caliciviridae; RNA genome of ~7,500 nucleotides 
− High mutation and recombination rates   high genetic variability 
− Non-enveloped virus with one major capsid protein 
− Survives heating and freezing, remains viable on dry surfaces for weeks 
 
 Highly contagious 
− As few as 18 particles can cause illness 
− Transmission by fecal-oral and aerosolized routes 
− Ingestion of contaminated foods or water 
− Handling of contaminated objects 
 
 Prolifically shed 
− Up to 5 billion doses of infectious virus can be shed by an ill person over the 
course of a few weeks, most of which is an asymptomatic period 
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Norovirus –The Burden of Disease1    
 One-fifth of all diarrhea cases globally 
 
  Greater than 200,000 deaths annually in kids < 5 years of age living in    
    developing countries 
 
  Principle cause of foodborne disease outbreaks in the United States 
 
  A key health care-acquired infection 
 




 1 Lopman, et al. (2016) PLoS Med 13(4) 
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• The norovirus disease burden is substantial, often causing extensive 
and wide-ranging disruption 1-3 








• The disruptive impact of norovirus-related disease is underestimated 




• Long-term health care 
facilities, nursing 
homes 














• Party, events 
Travelers 
 
• Cruise ships 
• Air, train and 
bus travel 
1. Glass RI NEJM 2009; 2. CDC MMWR 2011; 3. Koo HL J Clin Microbiol 2010; 4. Tam CC Gut 2012; 5. Beersma MF J Clin Microbiol 2012 
Military 
 
• Military camps 
• Deployed 
soldiers 
Disruption due to Norovirus 
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Global Economic Impact of Norovirus Illness1 
Model Simulation 1 Annual Economic Burden  (2013 USD)1 
Direct Health System Costs 2 $4.2 billion 




•Children < 5 years 
 
$ 60.3 billion 
 
$ 39.8 billion 
Cost per illness varied by region and age and was highest among adults ≥ 55 years 
1 Bartsch, SM et al (2016) PLoS ONE 11(4). Model simulation of 233 countries/ areas 
2 Outpatient visits and hospitalization – see reference (1) 
3 Productivity losses due to absenteeism and mortality costs – see reference (1) 
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− VLPs are engineered and expressed using state-of-the -art 
recombinant protein technologies 
− Stable, icosahedral T3 capsid assemblies (native conformation) 
− Diameter of about 40 nanometers; Mass of about 10 mDa  
− No viral genetic material, can not replicate and are thus non-infectious 
− Expression level is high using a scalable manufacturing platform 







Takeda’s Norovirus Antigens are Virus-Like-Particles 







Noroviruses are classified 
into 7 genogroups and 
>25 human genotypes1  
Different Norovirus 
genotypes contain largely 
conserved VP1 capsid 
protein structures 
Molecular models of a conserved 
Norovirus  structural protein that 
highlight amino acid differences. 
Courtesy of GI Para, NIH. 
Multiple genotype-specific 
sequences are combined 
into a single synthetic VP1 
capsid protein 
Molecular model of a synthetic protein 
containing antigenic determinants 
from three Norovirus genotypes. 
Courtesy of GI Para, NIH. 
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Virus-Like Particles Antigens (VLPs) 
Conformationally correct synthetic viral capsids 
Adjuvant (TBC) 
Potential to improve breadth of protection and to 
stimulate longer lasting immunity 




 multi-strain immunization 











E.g.  Takeda’s GII.4 
Consensus Strategy 
Epitopes from three different 




Included in vaccine 
Immuno-active adjuvants     
(e.g. MPL)   
Under investigation 
 The inclusion of immuno-
active adjuvants is being 
evaluated and will be driven 
by clinical results  
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Takeda’s Norovirus Vaccine Approach 
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Commercial-scale Manufacturing  
• Protein expression 
– Common platform for all Norovirus VLPs 
– Small footprint, single-use stirred-tank reactor  
– Serum-free media, suspension culture 
– Standard BSL-1 / Grade D recombinant protein facility 
 
• Protein purification 
– Chromatography and UF/DF steps performed with 
automated, disposable flow path skids  
– Bulk purified antigen stable long-term prior to Alum 
adsorption 
– VLPs characterized using contemporary protein 
analytical methods 
 
• Manufacturing operations 
– Standard, multi-product, multi-host Mfg facility  
– VLP productivity supports global supply from one small-
scale Mfg train 





Representative VLP Purity Data  
Attribute Specification Scale-Down Model  (N=3) 
Commercial Scale  
(N=4) 
Product Purity  
Test 1 ≥ 90% 100 100 
Product Purity  
Test 2 ≥ 90% 98 99 
Host Impurity  
Test 1 ≤ 10 µg/mg ≤ 0.52 < 0.001 
Host Impurity  
Test 2 ≤ 10 ng/mg ≤ 0.96 ≤ 0.001 
Host Impurity  
Test 3 ≤ 10 ng/mg ≤ 0.063 ≤ 0.001 
Process Impurity  
Test 1 ≤ 100 µg/mg Not tested < 0.14 
Process Impurity  
Test 2 ≤ 100 µg/mg Not tested < 0.02 
Process Impurity  
Test 3 ≤ 10 µg/mg Not tested < 0.24 
• Commercial scale VLPs are highly purified; similar results for other VLPs 
• Results from a 1/20th scale development model are comparable to full scale  
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Amino acid sequence 
Quaternary Structure Oligomers Tertiary/Secondary Structure Primary Structure 
VLP aggregates 
Micron Sub-micron Nanometer Ångström 
VLP Characterization Toolkit 
Laser Diffraction 
Electrophoretic mobility 












VLP   1   (red)  
VLP   2  (yellow) 
VLP 1 and VLP 2 adsorbed to  
adjuvant 
 Transmission Electron Microscopy can distinguish 
between VLPs with different primary structures 
Reconstruction from TEM images showing differences  
between VLP  1 and  VLP 2 
Cryo-TEM Micrograph Reconstructions 
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Cryo-TEM GI.1 and GII.4 VLPs  
GI.1 VLP GII.4 VLP 
Dependent on vaccine-specific amino acid sequences, particle shapes may vary   
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Manufacturing Reproducibility:  
SEC-MALS1 
The majority of the nanoparticle 
population  (97-98%) is 
monodisperse (10mDa) with 2-3% 
of the population existing in a 
dimeric state (20 mDa). 
 
 
1 SEC-MALS = size exclusion chromatography – 




Molar Mass 1 Molar Mass 2 LS UV RI 
time (min) 


















Manufacturing Reproducibility:  
Peptide mapping 
When digested with a mixture of proteases and then analyzed by mass spectrometry, the 
resulting VLP “fingerprint” was reproducible demonstrating consistent protein sequence 
21 
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Manufacturing Reproducibility:  
intact mass analysis 
• The VLPs are composed of a reproducible distribution of four capsid protein species  
• The species vary based on minor differences in the N- or C- terminal regions  
Amino acids 1-540 
Amino acids 4-540 
Amino acids 1-535 
Amino acids 4-535 
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Summary: Takeda’s Norovirus VLP Technology  
• Norovirus is highly contagious and is the leading cause of acute gastroenteritis 
worldwide.  There are hundreds of millions of cases of illness each year with 
up to 200,000 deaths in children < 5 years of age.  
• Takeda’s norovirus vaccine candidate is based on synthetic ~40 nm VLPs 
manufactured by a proprietary platform process that is highly portable and is 
designed to fit in standard recombinant protein facilities. 
• Tens of millions of highly purified VLP dose equivalents have already been 
produced at commercial scale.  
• VLPs have been characterized by a suite of advanced particle and protein 
analytical methods. 
• Drug product manufacturing for multiple formulations is operating at 
commercial scale at a sustainable cost-of-goods. 
• Takeda’s VLP manufacturing platform can be applied to multiple norovirus 
strains and other VLP-based vaccine candidates. 
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